We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Strategies for delivery and integration of evidence-based interventions
Overview of the UK's cancer research infrastructure and the advantages of investing in the UK's life science sector to develop new treatments.
Analyses patients’ and providers' perspectives on reasons for LFU
New 10-year plan to expand and improve the drug and alcohol workforce published.
First published during the 2022 to 2024 Sunak Conservative government
Overview of UK research infrastructure for genomics technologies, and advantages of investment in the UK's life science sector to support new products.
Report sets out findings of research into the challenges faced when developing treatments for dementia.
Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Evaluates shortened treatment regimens, versus standard six-month treatment regimen, in individuals with drug-sensitive pulmonary TB
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).